Metabolic and laboratory effects of a progestin-only pill containing drospirenone 4 mg in comparison to desogestrel 75 µg: a double-blind, double-dummy, prospective …
S Palacios, E Colli, PA Regidor - The European Journal of …, 2021 - Taylor & Francis
S Palacios, E Colli, PA Regidor
The European Journal of Contraception & Reproductive Health Care, 2021•Taylor & FrancisPurpose: Steroid hormones in hormonal contraceptives influence a variety of metabolic
parameters. Mainly, ethinyloestradiol (EE) in combined hormonal contraceptives (CHC) is a
potent inducer of hepatic coagulation factors, has an impact on cholesterol and triglyceride
levels and glucose tolerance. Progestins in CHC modify the oestrogen effects in different
ways, depending on their pharmacologic properties. The metabolic impact of progestin-only
contraceptives is generally considered low. Methods: The influence of novel drospirenone …
parameters. Mainly, ethinyloestradiol (EE) in combined hormonal contraceptives (CHC) is a
potent inducer of hepatic coagulation factors, has an impact on cholesterol and triglyceride
levels and glucose tolerance. Progestins in CHC modify the oestrogen effects in different
ways, depending on their pharmacologic properties. The metabolic impact of progestin-only
contraceptives is generally considered low. Methods: The influence of novel drospirenone …
Abstract
Purpose: Steroid hormones in hormonal contraceptives influence a variety of metabolic parameters. Mainly, ethinyloestradiol (EE) in combined hormonal contraceptives (CHC) is a potent inducer of hepatic coagulation factors, has an impact on cholesterol and triglyceride levels and glucose tolerance. Progestins in CHC modify the oestrogen effects in different ways, depending on their pharmacologic properties. The metabolic impact of progestin-only contraceptives is generally considered low.
Methods: The influence of novel drospirenone (DRSP)-only pill (4 mg DRSP in 24/4 intake) on a variety of lipid-, carbohydrate- and bone metabolic parameters and on haemostatic variables including clotting factors and D-Dimer level was evaluated in comparison to 0.075 mg desogestrel (DSG) during a multicentric, prospective, double-blind, double-dummy clinical trial with 1190 participants over nine treatment cycles.
Results: For both DRSP and DSG, there was a decrease in cholesterol (total, HDL, and LDL) and triglyceride levels. No relevant influence on glucose, insulin, and c-peptide levels or bone remodelling markers were detected in both treatment groups. Considering the coagulatory parameters, there was no impact on hemostasis.
Conclusions: The results confirm the beneficial properties of the drospirenone-only pill.
EudraCT Number: 2011-002396-42
Taylor & Francis Online以上显示的是最相近的搜索结果。 查看全部搜索结果